Durability of antibodies post vaccination with two doses of inactivated BBIBP-CorV vaccine
暂无分享,去创建一个
R. Halwani | P. Ogrodzki | S. Ganesan | W. Zaher | S. Mahmoud | Nawal Alkaabi | F. Cantarutti | N. Sharif-Askari | Hannah Wilson
[1] Wei-Gang Hu,et al. Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects , 2021, Frontiers in Cellular and Infection Microbiology.
[2] Scott M Elliott,et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial , 2021, The Lancet.
[3] Y. Kreiss,et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months , 2021, The New England journal of medicine.
[4] I. Suriapranata,et al. Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia , 2021, International Journal of Infectious Diseases.
[5] F. Can,et al. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID‐19 infection: Prospective observational study , 2021, Journal of medical virology.
[6] L. Tserel,et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.
[7] L. Heylen,et al. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.
[8] E. Callaway. COVID vaccine boosters: the most important questions , 2021, Nature.
[9] G. Shurin,et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects , 2021, Microbiology spectrum.
[10] Yu Li,et al. SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients , 2021, Cellular & Molecular Immunology.
[11] A. Huppert,et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.
[12] C. Swanton,et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination , 2021, The Lancet.
[13] L. Abu-Raddad,et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants , 2021, The New England journal of medicine.
[14] R. Darnell,et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants , 2021, The New England journal of medicine.
[15] A. Huppert,et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals , 2021, Nature Medicine.
[16] D. Stuart,et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.
[17] D. Cummings,et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.
[18] Matthew S. Miller,et al. Immunological considerations for COVID-19 vaccine strategies , 2020, Nature Reviews Immunology.
[19] Gary F. Templeton. A Two-Step Approach for Transforming Continuous Variables to Normal: Implications and Recommendations for IS Research , 2011, Commun. Assoc. Inf. Syst..